Dupuytren’s Disease

  1. Verjee LS, Verhoekx J, Chan J, Krausgruber T, Nicolaidou V, Izadi D, Davidson D, Feldmann M, Midwood KS, Nanchahal J (2013). Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a novel therapeutic target. Proceedings of the National Academy of Sciences, USA. 110: E928-937
  2. Verhoekx J, Verjee LS, Izadi D, Chan J, Nicolaidou V, Davidson D, Midwood KS, Nanchahal J (2013). Isometric contraction of Dupuytren’s myofibroblasts is inhibited by blocking intracellular connections. Journal of Investigative Dermatology. 133(12): 2664-71
  3. Verjee L, Midwood K, Davidson D, Eastwood M, Nanchahal J (2010). Post-transcriptional regulation of a-smooth muscle actin determines the contractile phenotype of Dupuytren’s nodular cells. Journal of Cellular Physiology, 224(3): 681-90.
  4. Hindocha S, McGrouther DA, Bayat A (2009). Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand. 4: 256-269